🇺🇸 FDA

Intelligence Platform

Patents

Browse 24 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12390453

Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12336983

Inhibition of crystal growth of roflumilast

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12329751

Topical roflumilast formulation having antifungal properties

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12310956

Topical roflumilast formulation having improved delivery and plasma half-life

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12257242

Inhibition of crystal growth of roflumilast

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12220409

Roflumilast formulations with an improved pharmacokinetic profile

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12161643

Stable formulations of SHR0302

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144802

Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12083122

Laureth-4 containing topical formulations

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12053481

Compositions and methods for deep dermal drug delivery

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12042487

Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12042558

Method and formulation for improving roflumilast skin penetration lag time

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12016848

Roflumilast formulations with an improved pharmacokinetic profile

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12011437

Roflumilast formulations with an improved pharmacokinetic profile

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12005051

Topical roflumilast formulation having improved delivery and plasma half life

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12005052

Topical roflumilast formulation having improved delivery and plasma half-life

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11992480

Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11819496

Topical roflumilast formulation having improved delivery and plasma half-life

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11793796

Inhibition of crystal growth of roflumilast

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11730740

Laureth-4 containing topical formulations

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11707454

Topical roflumilast formulation having antifungal properties

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11628177

Compositions and methods for deep dermal drug delivery

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11534493

Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceut

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11129818

Topical roflumilast formulation having improved delivery and plasma half life

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted